Adicet Bio 10-Q 3 Nov 16 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Sep. 30, 2016	Nov. 01, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	ACETO CORP
Entity Central Index Key	2,034
Trading Symbol	acet
Current Fiscal Year End Date	--06-30
Entity Filer Category	Large Accelerated Filer
Entity Common Stock Shares Outstanding		30,051,333
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Amendment Flag	false
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016
Current assets:
Cash and cash equivalents	$ 73,142	$ 66,828
Investments	1,910	881
Trade receivables, less allowance for doubtful accounts (September 30, 2016, $456; June 30, 2016, $513)	158,744	167,612
Other receivables	11,638	12,650
Inventory	104,456	98,107
Prepaid expenses and other current assets	4,324	3,339
Deferred income tax asset, net	1,843	3,244
Total current assets	356,057	352,661
Property and equipment, net	10,216	10,044
Property held for sale	6,868	6,868
Goodwill	67,880	67,871
Intangible assets, net	77,884	79,071
Deferred income tax asset, net	17,594	18,053
Other assets	8,196	6,210
TOTAL ASSETS	544,695	540,778
Current liabilities:
Current portion of long-term debt	197	197
Accounts payable	49,271	46,034
Accrued expenses	43,729	52,675
Total current liabilities	93,197	98,906
Long-term debt, net	119,975	118,592
Long-term liabilities	6,651	6,344
Environmental remediation liability	6,372	3,352
Deferred income tax liability	8,677	9,142
Total liabilities	234,872	236,336
Commitments and contingencies (Note 6)
Shareholders' equity:
Preferred stock, 2,000 shares authorized; no shares issued and outstanding
Common stock, $.01 par value, 75,000 shares authorized; 30,049 and 29,595 shares issued and outstanding at September 30, 2016 and June 30, 2016, respectively	300	296
Capital in excess of par value	118,053	115,667
Retained earnings	197,235	194,804
Accumulated other comprehensive loss	(5,765)	(6,325)
Total shareholders' equity	309,823	304,442
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 544,695	$ 540,778

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($) shares in Thousands, $ in Thousands	Sep. 30, 2016	Jun. 30, 2016
Statement Of Financial Position [Abstract]
Trade receivables, allowance for doubtful accounts (in dollars)	$ 456	$ 513
Preferred stock, shares authorized	2,000	2,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	75,000	75,000
Common stock, shares issued	30,049	29,595
Common stock, shares outstanding	30,049	29,595

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Income Statement [Abstract]
Net sales	$ 128,018	$ 133,500
Cost of sales	97,179	98,919
Gross profit	30,839	34,581
Selling, general and administrative expenses	21,024	17,633
Research and development expenses	1,050	1,430
Operating income	8,765	15,518
Other (expense) income:
Interest expense	(2,233)	(754)
Interest and other income, net	248	219
Other (expense) income, Total	(1,985)	(535)
Income before income taxes	6,780	14,983
Provision for income taxes	2,395	5,685
Net income	$ 4,385	$ 9,298
Basic income per common share (in dollars per share)	$ 0.15	$ 0.32
Diluted income per common share (in dollars per share)	$ 0.15	$ 0.32
Weighted average shares outstanding:
Basic (in shares)	29,518	28,983
Diluted (in shares)	29,840	29,392

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Statement of Comprehensive (loss) Income [Abstract]
Net income	$ 4,385	$ 9,298
Other comprehensive income:
Foreign currency translation adjustments	560	1,066
Change in fair value of interest rate swaps		(149)
Comprehensive income	$ 4,945	$ 10,215

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Operating activities:
Net income	$ 4,385	$ 9,298
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	3,168	3,089
Amortization of debt issuance costs and debt discount	1,432
Provision for doubtful accounts	(58)	25
Non-cash stock compensation	1,664	1,467
Deferred income taxes	1,405	477
Environmental remediation charge	170
Earnings on equity investment in joint venture	(325)	(109)
Changes in assets and liabilities:
Trade accounts receivable	9,141	(6,126)
Other receivables	464	1,051
Inventory	(6,105)	5,607
Prepaid expenses and other current assets	(978)	(1,153)
Other assets	(305)	106
Accounts payable	3,135	(5,821)
Accrued expenses and other liabilities	(6,543)	(4,937)
Net cash provided by operating activities	10,650	2,974
Investing activities:
Purchases of investments	(1,017)	(16)
Sales of investments		1,006
Payments for intangible assets	(1,594)	(6,450)
Purchases of property and equipment, net	(541)	(312)
Net cash used in investing activities	(3,152)	(5,772)
Financing activities:
Payment of cash dividends	(1,954)
Proceeds from exercise of stock options	185	115
Excess tax benefit on stock option exercises and restricted stock	437	820
Payment of contingent consideration		(1,500)
Borrowings of bank loans		10,500
Repayment of bank loans	(49)	(10,549)
Net cash used in financing activities	(1,381)	(614)
Effect of exchange rate changes on cash	197	222
Net increase (decrease) in cash	6,314	(3,190)
Cash and cash equivalents at beginning of period	66,828	34,020
Cash and cash equivalents at end of period	$ 73,142	$ 30,830

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parentheticals) (unaudited) $ in Thousands	Sep. 30, 2015USD ($)
Statement of Cash Flows [Abstract]
Dividends declared but not paid	$ 1,745

Basis of Presentation

Basis of Presentation	3 Months Ended
	Sep. 30, 2016
Basis Of Presentation [Abstract]
Basis of Presentation	(1) Basis of Presentation The condensed consolidated financial statements of Aceto Corporation and subsidiaries (“Aceto” or the “Company”) included herein have been prepared by the Company and reflect all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for all periods presented. Interim results are not necessarily indicative of results which may be achieved for the full year. The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses reported in those financial statements and the disclosure of contingent assets and liabilities at the date of the financial statements. These judgments can be subjective and complex, and consequently actual results could differ from those estimates and assumptions. The Company’s most critical accounting policies relate to revenue recognition; allowance for doubtful accounts; inventory; goodwill and other indefinite-life intangible assets; long-lived assets; environmental matters and other contingencies; income taxes; and stock-based compensation. These condensed consolidated financial statements do not include all disclosures associated with consolidated financial statements prepared in accordance with GAAP. Accordingly, these statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto contained in the Company’s Form 10-K for the year ended June 30, 2016.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	(2) Stock-Based Compensation At the annual meeting of shareholders of the Company, held on December 15, 2015, the Company’s shareholders approved the Aceto Corporation 2015 Equity Participation Plan (the “2015 Plan”). Under the 2015 Plan, grants of stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards (“Stock Awards”) may be offered to employees, non-employee directors, consultants and advisors of the Company, including the chief executive officer, chief financial officer and other named executive officers. The maximum number of shares of common stock of the Company that may be issued pursuant to Stock Awards granted under the 2015 Plan will not exceed, in the aggregate, 4,250 shares. Stock Awards that are intended to qualify as “performance-based compensation” for purposes of Section 162(m) of the Internal Revenue Code of 1986, as amended, may be granted. Performance-based awards may be granted, vested and paid based on the attainment of specified performance goals. At the annual meeting of shareholders of the Company, held on December 6, 2012, the Company’s shareholders approved the amended and restated Aceto Corporation 2010 Equity Participation Plan (the “2010 Plan”). Under the 2010 Plan, grants of stock options, restricted stock, restricted stock units, stock appreciation rights, and stock bonuses may be made to employees, non-employee directors and consultants of the Company. The maximum number of shares of common stock of the Company that may be issued pursuant to awards granted under the 2010 Plan will not exceed, in the aggregate, 5,250 shares. In addition, restricted stock may be granted to an eligible participant in lieu of a portion of any annual cash bonus earned by such participant. Such award may include additional shares of restricted stock (premium shares) greater than the portion of bonus paid in restricted stock. The restricted stock award is vested at issuance and the restrictions lapse ratably over a period of years as determined by the Board of Directors, generally three years. The premium shares vest when all the restrictions lapse, provided that the participant remains employed by the Company at that time. During the three months ended September 30, 2016, the Company granted 256 shares of restricted common stock to its employees that vest over three years and 42 restricted stock units to its employees that have varying vest dates through July 2017. In addition, the Company also issued a target grant of 160 performance-vested restricted stock units, which grant could be as much as 280 units if certain performance criteria and market conditions are met. Performance-vested restricted stock units will cliff vest 100% at the end of the third year following grant in accordance with the performance metrics set forth in the applicable employee performance-vested restricted stock unit grant. In September 2016, the Company granted 28 performance stock options to an executive officer at an exercise price of $20.03 per share. The performance options vest if the closing stock price meets or exceeds the target price of $40 for 20 consecutive trading days prior to June 30, 2021 and the explicit service period of 1 year has been met. During the year ended June 30, 2016, the Company granted 221 shares of restricted common stock to its employees that vest over three years and 14 shares of restricted common stock to its non-employee directors, which vest over approximately one year as well as 46 restricted stock units that have varying vest dates through July 2017. In addition, the Company also issued a target grant of 142 performance-vested restricted stock units, which grant could be as much as 248 if certain performance criteria and market conditions are met. Performance-vested restricted stock units will cliff vest 100% at the end of the third year following grant in accordance with the performance metrics set forth in the applicable employee performance-vested restricted stock unit grant. For the three months ended September 30, 2016 and 2015, the Company recorded stock-based compensation expense of approximately $1,659 and $1,462, respectively, related to restricted common stock, restricted stock units and stock options. As of September 30, 2016, the total unrecognized stock-based compensation cost is approximately $15,142.

Capital Stock

Capital Stock	3 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Capital Stock	(3) Capital Stock On August 25, 2016, the Company's board of directors declared a regular quarterly dividend of $0.065 per share which was paid on September 20, 2016 to shareholders of record as of September 9, 2016. On May 8, 2014, the Board of Directors of the Company authorized the continuation of the Company’s stock repurchase program, expiring in May 2017. Under the stock repurchase program, the Company is authorized to purchase up to 5,000 shares of common stock in open market or private transactions, at prices not to exceed the market value of the common stock at the time of such purchase. The Company is authorized to issue 75,000 shares of Common Stock and 2,000 shares of Preferred Stock. The Board of Directors has authority under the Company’s Restated Certificate of Incorporation to issue shares of preferred stock with voting and other relative rights to be determined by the Board of Directors.

Net Income Per Common Share

Net Income Per Common Share	3 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Net Income Per Common Share	(4) Net Income Per Common Share Basic income per common share is based on the weighted average number of common shares outstanding during the period. Diluted income per common share includes the dilutive effect of potential common shares outstanding. The following table sets forth the reconciliation of weighted average shares outstanding and diluted weighted average shares outstanding: Three months Ended 2016 2015 Weighted average shares outstanding 29,518 28,983 Dilutive effect of stock options and restricted stock awards and units 322 409 Diluted weighted average shares outstanding 29,840 29,392 The Convertible Senior Notes (see Note 5) will only be included in the dilutive net income per share calculations using the treasury stock method during periods in which the average market price of Aceto’s common stock is above the applicable conversion price of the Convertible Senior Notes, or $33.215 per share, and the impact would not be anti-dilutive.

Debt

Debt	3 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Debt	(5) Debt Long-term debt September 30, June 30, Convertible Senior Notes, net $ 117,261 $ 115,829 Mortgage 2,911 2,960 120,172 118,789 Less current portion 197 197 $ 119,975 $ 118,592 Convertible Senior Notes In November 2015, Aceto offered $125,000 aggregate principal amount of Convertible Senior Notes due 2020 (the "Notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. In addition, Aceto granted the initial purchasers for the offering an option to purchase up to an additional $18,750 aggregate principal amount pursuant to the initial purchasers’ option to purchase additional Notes, which was exercised in November 2015. Therefore the total offering was $143,750 aggregate principal amount. The Notes are unsecured obligations of Aceto and rank senior in right of payment to any of Aceto’s subordinated indebtedness, equal in right of payment to all of Aceto’s unsecured indebtedness that is not subordinated, effectively junior in right of payment to any of Aceto’s secured indebtedness to the extent of the value of the assets securing such indebtedness and structurally junior in right of payment to all indebtedness and other liabilities (including trade payables) of Aceto’s subsidiaries. Interest will be payable semi-annually in arrears. The Notes will be convertible into cash, shares of Aceto common stock or a combination thereof, at Aceto’s election, upon the satisfaction of specified conditions and during certain periods. The Notes will mature in November 2020. The Notes pay 2.0% interest semi-annually in arrears on May 1 and November 1 of each year, which commenced on May 1, 2016. The Notes are convertible into 4,328 shares of common stock, based on an initial conversion price of $33.215 per share. Holders may convert all or any portion of their notes, in multiples of one thousand dollar principal amount, at their option at any time prior to the close of business on the business day immediately preceding May 1, 2020 only under the following circumstances: (i) during any calendar quarter (and only during such calendar quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day, (ii) during the five consecutive business day period after any five consecutive trading day period (which is referred to as the “measurement period”) in which the trading price per one thousand dollar principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of Aceto’s common stock and the conversion rate on each such trading day; or (iii) upon the occurrence of specified corporate events. Upon conversion by the holders, the Company may elect to settle such conversion in shares of its common stock, cash, or a combination thereof. As a result of its cash conversion option, the Company separately accounted for the value of the embedded conversion option as a debt discount (with an offset to capital in excess of par value). The debt discount is being amortized as additional non-cash interest expense using the effective interest method over the term of the Notes. Debt issuance costs are being amortized as additional non-cash interest expense using the straight-line method over the term of the debt, since this method was not significantly different from the effective interest method. In connection with the offering of the Notes, Aceto entered into privately negotiated convertible note hedge transactions with option counterparties, which are affiliates of certain of the initial purchasers. The convertible note hedge transactions are expected generally to reduce the potential dilution to Aceto’s common stock and/or offset any cash payments Aceto is required to make in excess of the principal amount of converted Notes upon any conversion of Notes. Aceto also entered into privately negotiated warrant transactions with the option counterparties. The warrant transactions could separately have a dilutive effect to the extent that the market price per share of Aceto’s common stock as measured over the applicable valuation period at the maturity of the warrants exceeds the applicable strike price of the warrants. By entering into these transactions with the option counterparties, the Company issued convertible debt and a freestanding “call-spread.” The carrying value of the Notes is as follows: September 30, June 30, Principal amount $ 143,750 $ 143,750 Unamortized debt discount (23,044 ) (24,267 ) Unamortized debt issuance costs (3,445 ) (3,654 ) Net carrying value $ 117,261 $ 115,829 The following table sets forth the components of total “interest expense” related to the Notes recognized in the accompanying consolidated statements of income for the three months ended September 30: Three months Ended September 30, 2016 Contractual coupon $ 725 Amortization of debt discount 1,223 Amortization of debt issuance costs 209 $ 2,157 Credit Facilities On October 28, 2015, the Company entered into an Amended and Restated Credit Agreement (the “A&R Credit Agreement”), which amended and restated in its entirety the Credit Agreement, dated as of April 30, 2014 with three domestic financial institutions, as amended on June 25, 2015 by Amendment No. 1 to the Credit Agreement (together, the “First Amended Credit Agreement”). The A&R Credit Agreement increases the aggregate available revolving commitment under the First Amended Credit Agreement from $75,000 to an initial aggregate available revolving commitment of $150,000 (the “Initial Revolving Commitment”), which may be increased in accordance with the terms and conditions of the A&R Credit Agreement by an aggregate amount not to exceed $100,000 (the “Expansion Commitment” and, together with the Initial Revolving Commitment, the “Revolving Commitment”). Under the A&R Credit Agreement, the Company may borrow, repay and reborrow loans up to the Revolving Commitment from and as of October 28, 2015, to but excluding the earlier of October 28, 2020 and the termination of the Revolving Commitment, in amounts up to, but not exceeding at any one time, the Revolving Commitment. The A&R Credit Agreement does not provide for any term loan commitment. The proceeds from initial borrowings under the A&R Credit Agreement have been used to repay all amounts outstanding pursuant to the term loan commitment and revolving loan commitment under Aceto’s First Amended Credit Agreement. The proceeds from the issuance of the Notes were used to pay initial borrowings under the A&R Credit Agreement. As of September 30, 2016, there were no amounts outstanding under the A&R Credit Agreement. The A&R Credit Agreement provides for (i) Eurodollar Loans (as such term is defined in the A&R Credit Agreement), (ii) ABR Loans (as such term is defined in the A&R Credit Agreement) or (iii) a combination thereof. Borrowings under the A&R Credit Agreement will bear interest per annum at a base rate or, at the Company’s option, LIBOR, plus an applicable margin ranging from 0.00% to 0.75% in the case of ABR Loans, and 1.00% to 1.75% in the case of Eurodollar Loans. The applicable interest rate margin percentage will be determined by the Company’s senior secured net leverage ratio. The A&R Credit Agreement, similar to Aceto’s First Amended Credit Agreement, provides that commercial letters of credit shall be issued to provide the primary payment mechanism in connection with the purchase of any materials, goods or services in the ordinary course of business. The Company had no open letters of credit at September 30, 2016 and June 30, 2016. The A&R Credit Agreement, like Aceto’s First Amended Credit Agreement, provides for a security interest in substantially all of the personal property of the Company and certain of its subsidiaries. The A&R Credit Agreement contains several financial covenants including, among other things, maintaining a minimum level of debt service. Under the A&R Credit Agreement, the Company and its subsidiaries are also subject to certain restrictive covenants, including, among other things, covenants governing liens, limitations on indebtedness, limitations on guarantees, limitations on sales of assets and sales of receivables, and limitations on loans and investments. The Company was in compliance with all covenants at September 30, 2016. Mortgage On June 30, 2011, the Company entered into a mortgage payable for $3,947 on its corporate headquarters, in Port Washington, New York. This mortgage payable is secured by the land and building and is being amortized over a period of 20 years. The mortgage payable, which was modified in October 2013, bears interest at 4.92% per annum as of September 30, 2016 and matures on June 30, 2021.

Commitments, Contingencies and

Commitments, Contingencies and Other Matters	3 Months Ended
	Sep. 30, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments, Contingencies and Other Matters	(6) Commitments, Contingencies and Other Matters The Company and its subsidiaries are subject to various claims which have arisen in the normal course of business. The Company provides for costs related to contingencies when a loss from such claims is probable and the amount is reasonably determinable. In determining whether it is possible to provide an estimate of loss, or range of possible loss, the Company reviews and evaluates its litigation and regulatory matters on a quarterly basis in light of potentially relevant factual and legal developments. If the Company determines an unfavorable outcome is not probable or reasonably estimable, the Company does not accrue for a potential litigation loss. While the Company has determined that there is a reasonable possibility that a loss has been incurred, no amounts have been recognized in the financial statements, other than what has been discussed below, because the amount of the liability cannot be reasonably estimated at this time. In fiscal years 2011, 2009, 2008 and 2007, the Company received letters from the Pulvair Site Group, a group of potentially responsible parties (PRP Group) who are working with the State of Tennessee (the State) to remediate a contaminated property in Tennessee called the Pulvair site. The PRP Group has alleged that Aceto shipped hazardous substances to the site which were released into the environment. The State had begun administrative proceedings against the members of the PRP Group and Aceto with respect to the cleanup of the Pulvair site and the PRP Group has begun to undertake cleanup. The PRP Group is seeking a settlement of approximately $1,700 from the Company for its share to remediate the site contamination. Although the Company acknowledges that it shipped materials to the site for formulation over twenty years ago, the Company believes that the evidence does not show that the hazardous materials sent by Aceto to the site have significantly contributed to the contamination of the environment and thus believes that, at most, it is a de minimis contributor to the site contamination. Accordingly, the Company believes that the settlement offer is unreasonable. Management believes that the ultimate outcome of this matter will not have a material adverse effect on the Company's financial condition or liquidity. The Company has environmental remediation obligations in connection with Arsynco, Inc. (“Arsynco”), a subsidiary formerly involved in manufacturing chemicals located in Carlstadt, New Jersey, which was closed in 1993 and is currently held for sale. Based on continued monitoring of the contamination at the site and the approved plan of remediation, Arsynco received an estimate from an environmental consultant stating that the costs of remediation could be between $19,700 and $21,500. Remediation commenced in fiscal 2010, and as of September 30, 2016 and June 30, 2016, a liability of $10,035 and $12,532, respectively, is included in the accompanying consolidated balance sheets for this matter. In the three months ended September 30, 2016, $170 environmental remediation charge was recorded and included in selling, general and administrative expenses in the accompanying consolidated statement of income. In accordance with GAAP, management believes that the majority of costs incurred to remediate the site will be capitalized in preparing the property which is currently classified as held for sale. An appraisal of the fair value of the property by a third-party appraiser supports the assumption that the expected fair value after the remediation is in excess of the amount required to be capitalized. However, these matters, if resolved in a manner different from those assumed in current estimates, could have a material adverse effect on the Company’s financial condition, operating results and cash flows when resolved in a future reporting period. In connection with the environmental remediation obligation for Arsynco, in July 2009, Arsynco entered into a settlement agreement with BASF Corporation (“BASF”), the former owners of the Arsynco property. In accordance with the settlement agreement, BASF paid for a portion of the prior remediation costs and going forward, will co-remediate the property with the Company. The contract requires that BASF pay $550 related to past response costs and pay a proportionate share of the future remediation costs. Accordingly, the Company had recorded a gain of $550 in fiscal 2009. This $550 gain relates to the partial reimbursement of costs of approximately $1,200 that the Company had previously expensed. The Company also recorded an additional receivable from BASF, with an offset against property held for sale, representing its estimated portion of the future remediation costs. The balance of this receivable for future remediation costs as of September 30, 2016 and June 30, 2016 is $4,515 and $5,639, respectively, which is included in the accompanying consolidated balance sheets. In March 2006, Arsynco received notice from the EPA of its status as a PRP under the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA) for a site described as the Berry’s Creek Study Area (“BCSA”). Arsynco is one of over 150 PRPs which have potential liability for the required investigation and remediation of the site. The estimate of the potential liability is not quantifiable for a number of reasons, including the difficulty in determining the extent of contamination and the length of time remediation may require. In addition, any estimate of liability must also consider the number of other PRPs and their financial strength. In July 2014, Arsynco received notice from the U.S. Department of Interior (“USDOI”) regarding the USDOI’s intent to perform a Natural Resource Damage (NRD) Assessment at the BCSA. Arsynco has to date declined to participate in the development and performance of the NRD assessment process. Based on prior practice in similar situations, it is possible that the State may assert a claim for natural resource damages with respect to the Arsynco site itself, and either the federal government or the State (or both) may assert claims against Arsynco for natural resource damages in connection with Berry's Creek; any such claim with respect to Berry's Creek could also be asserted against the approximately 150 PRPs which the EPA has identified in connection with that site. Any claim for natural resource damages with respect to the Arsynco site itself may also be asserted against BASF, the former owners of the Arsynco property. In September 2012, Arsynco entered into an agreement with three of the other PRPs that had previously been impleaded into New Jersey Department of Environmental Protection, et al. v. Occidental Chemical Corporation, et al., Docket No. ESX-L-9868-05 (the "NJDEP Litigation") and were considering impleading Arsynco into the same proceeding. Arsynco entered into an agreement to avoid impleader. Pursuant to the agreement, Arsynco agreed to (1) a tolling period that would not be included when computing the running of any statute of limitations that might provide a defense to the NJDEP Litigation; (2) the waiver of certain issue preclusion defenses in the NJDEP Litigation; and (3) arbitration of certain potential future liability allocation claims if the other parties to the agreement are barred by a court of competent jurisdiction from proceeding against Arsynco. In July 2015, Arsynco was contacted by an allocation consultant retained by a group of the named PRPs, inviting Arsynco to participate in the allocation among the PRPs’ investigation and remediation costs relating to the BCSA. Arsynco declined that invitation. Since an amount of the liability cannot be reasonably estimated at this time, no accrual is recorded for these potential future costs. The impact of the resolution of this matter on the Company’s results of operations in a particular reporting period is not currently known. A subsidiary of the Company markets certain agricultural protection products which are subject to the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA). FIFRA requires that test data be provided to the EPA to register, obtain and maintain approved labels for pesticide products. The EPA requires that follow-on registrants of these products compensate the initial registrant for the cost of producing the necessary test data on a basis prescribed in the FIFRA regulations. Follow-on registrants do not themselves generate or contract for the data. However, when FIFRA requirements mandate that new test data be generated to enable all registrants to continue marketing a pesticide product, often both the initial and follow-on registrants establish a task force to jointly undertake the testing effort. The Company is presently a member of several such task force groups, which requires payments for such memberships. In addition, in connection with our agricultural protection business, the Company plans to acquire product registrations and related data filed with the United States Environmental Protection Agency to support such registrations and other supporting data for several products. The acquisition of these product registrations and related data filed with the United States Environmental Protection Agency as well as payments to various task force groups could approximate $1,826 through fiscal 2017.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	(7) Fair Value Measurements GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly fashion between market participants at the measurement date. GAAP establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s assumptions (unobservable inputs). The hierarchy consists of three levels: Level 1 – Quoted market prices in active markets for identical assets or liabilities; Level 2 – Inputs other than Level 1 inputs that are either directly or indirectly observable; and Level 3 – Unobservable inputs that are not corroborated by market data. On a recurring basis, Aceto measures at fair value certain financial assets and liabilities, which consist of cash equivalents, investments and foreign currency contracts. The Company classifies cash equivalents and investments within Level 1 if quoted prices are available in active markets. Level 1 assets include instruments valued based on quoted market prices in active markets which generally include corporate equity securities publicly traded on major exchanges. Time deposits are very short-term in nature and are accordingly valued at cost plus accrued interest, which approximates fair value, and are classified within Level 2 of the valuation hierarchy. The Company uses foreign currency futures contracts to minimize the risk caused by foreign currency fluctuation on its foreign currency receivables and payables by purchasing futures with one of its financial institutions. Futures are traded on regulated U.S. and international exchanges and represent commitments to purchase or sell a particular foreign currency at a future date and at a specific price. Aceto’s foreign currency derivative contracts are classified within Level 2 as the fair value of these hedges is primarily based on observable futures foreign exchange rates. At September 30, 2016, the Company had foreign currency contracts outstanding that had a notional amount of $55,921. Unrealized losses on hedging activities for the three months ended September 30, 2016 and 2015 was $36 and $251, respectively, and are included in interest and other income, net, in the consolidated statements of income. The contracts have varying maturities of less than one year. During the fourth quarter of each year, the Company evaluates goodwill for impairment at the reporting unit level using a discounted cash flow model using Level 3 inputs. Additionally, on a nonrecurring basis, the Company uses fair value measures when analyzing asset impairment. Long-lived assets and certain identifiable intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If it is determined such indicators are present and the review indicates that the assets will not be fully recoverable, based on undiscounted estimated cash flows over the remaining amortization periods, their carrying values are reduced to estimated fair value. Measurements based on undiscounted cash flows are considered to be Level 3 inputs. In November 2015, the Company issued $143,750 aggregate principal amount of Notes (see Note 5). Since Aceto has the option to settle the potential conversion of the Notes in cash, the Company separated the embedded conversion option feature from the debt feature and accounts for each component separately, based on the fair value of the debt component assuming no conversion option. The calculation of the fair value of the debt component required the use of Level 3 inputs, and was determined by calculating the fair value of similar non-convertible debt, using a theoretical borrowing rate of 6.5%. The value of the embedded conversion option was determined using an expected present value technique (income approach) to estimate the fair value of similar non-convertible debt onvertible investors’ credit assumptions and high yield bond indices. The Notes approximate a full fair value of $131,800 at September 30, 2016 giving effect for certain factors, including the term of the Notes, current stock price of Aceto stock and effective interest rate. The carrying values of all financial instruments classified as a current asset or current liability are deemed to approximate fair value because of the short maturity of these instruments. The fair values of the Company’s notes receivable and short-term and long-term bank loans were based upon current rates offered for similar financial instruments to the Company. The following tables summarize the valuation of the Company’s financial assets and liabilities which were determined by using the following inputs at September 30, 2016 and June 30, 2016: Fair Value Measurements at September 30, 2016 Using Quoted Prices Significant Significant Total Cash equivalents: Time deposits - $ 6,292 - $ 6,292 Investments: Time deposits - 1,910 - 1,910 Foreign currency contracts-liabilities (1) - 38 - 38 Contingent consideration (2) - - $ 135 135 (1) Included in “Accrued expenses” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2016. (2) Included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2016. Fair Value Measurements at June 30, 2016 Using Quoted Prices Significant Significant Total Cash equivalents: Time deposits - $ 6,249 - $ 6,249 Investments: Time deposits - 881 - 881 Foreign currency contracts-assets (3) - 160 - 160 Foreign currency contracts-liabilities (4) - 169 - 169 Contingent consideration (5) - - $ 132 132 (3) Included in “Other receivables” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2016. (4) Included in “Accrued expenses” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2016. (5) Included in “Long-term liabilities” in the accompanying Consolidated Balance Sheet as of June 30, 2016.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	3 Months Ended
	Sep. 30, 2016
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Recent Accounting Pronouncements	(8) Recent Accounting Pronouncements In August 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740) Balance Sheet Classification of Deferred Assets. In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330) Simplifying the Measurement of Inventory. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40) In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), Revenue from Contracts with Customers - Deferral of the Effective Date Revenue from Contracts with Customers - Principal versus Agent Considerations (Reporting Revenue Gross versus Net) Revenue from Contracts with Customers - Identifying Performance Obligations and Licensing Revenue from Contracts with Customers - Narrow Scope Improvements and Practical Expedients,

Segment Information

Segment Information	3 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Segment Information	(9) Segment Information The Company's business is organized along product lines into three principal segments: Human Health, Pharmaceutical Ingredients and Performance Chemicals. Human Health Pharmaceutical Ingredients – Performance Chemicals Agricultural Protection Products include herbicides, fungicides and insecticides that control weed growth as well as control the spread of insects and other microorganisms that can severely damage plant growth. The Company's chief operating decision maker evaluates performance of the segments based on net sales, gross profit and income before income taxes. Unallocated corporate amounts are deemed by the Company as administrative, oversight costs, not managed by the segment managers. The Company does not allocate assets by segment because the chief operating decision maker does not review the assets by segment to assess the segments' performance, as the assets are managed on an entity-wide basis. During all periods presented, our chief operating decision maker has been the Chief Executive Officer of the Company. In accordance with GAAP, the Company has aggregated certain operating segments into reportable segments because they have similar economic characteristics, and the operating segments are similar in all of the following areas: (a) the nature of the products and services; (b) the nature of the production processes; (c) the type or class of customer for their products and services; (d) the methods used to distribute their products or provide their services; and (e) the nature of the regulatory environment. Three months Ended September 30, 2016 and 2015: Human Pharmaceutical Performance Unallocated Consolidated 2016 Net sales $ 47,889 $ 40,616 $ 39,513 $ - $ 128,018 Gross profit 14,205 6,954 9,680 - 30,839 Income (loss) before income taxes 3,972 3,067 4,832 (5,091 ) 6,780 2015 Net sales $ 57,481 $ 38,360 $ 37,659 $ - $ 133,500 Gross profit 20,309 6,114 8,158 - 34,581 Income (loss) before income taxes 10,503 2,099 3,544 (1,163 ) 14,983

Subsequent Event

Subsequent Event	3 Months Ended
	Sep. 30, 2016
Subsequent Events [Abstract]
Subsequent Event	(10) Subsequent Event On November 2, 2016, Aceto and two newly-formed wholly-owned subsidiaries of Rising entered into a product purchase agreement (the “Purchase Agreement”) with Citron Pharma LLC (“Citron”), Lucid Pharma LLC (“Lucid” and together with Citron, the “Sellers”) and certain related parties to purchase certain launched and unlaunched products and related assets, and assume certain liabilities, of the Sellers’ generic pharmaceutical businesses. The purchase price is comprised of: (i) $320,000 in cash, of which $270,000 is payable on the closing date of the acquisition and $50,000 is payable no sooner than the fifth anniversary of the closing date; (ii) approximately 5,122 shares of the Company’s common stock, 75% of which will be issued to the Sellers on the third anniversary of the closing and 25% of which will be issued on the fourth anniversary of the closing, subject to certain acceleration or deferral events; and (iii) up to $50,000 in cash earn-out payments.

Accounting Policies (Policies)

Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The condensed consolidated financial statements of Aceto Corporation and subsidiaries (“Aceto” or the “Company”) included herein have been prepared by the Company and reflect all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for all periods presented. Interim results are not necessarily indicative of results which may be achieved for the full year. The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses reported in those financial statements and the disclosure of contingent assets and liabilities at the date of the financial statements. These judgments can be subjective and complex, and consequently actual results could differ from those estimates and assumptions. The Company’s most critical accounting policies relate to revenue recognition; allowance for doubtful accounts; inventory; goodwill and other indefinite-life intangible assets; long-lived assets; environmental matters and other contingencies; income taxes; and stock-based compensation. These condensed consolidated financial statements do not include all disclosures associated with consolidated financial statements prepared in accordance with GAAP. Accordingly, these statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto contained in the Company’s Form 10-K for the year ended June 30, 2016.

Net Income Per Common Share (Ta

Net Income Per Common Share (Tables)	3 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Schedule of reconciliation of weighted average shares outstanding and diluted weighted average shares outstanding	Three months Ended 2016 2015 Weighted average shares outstanding 29,518 28,983 Dilutive effect of stock options and restricted stock awards and units 322 409 Diluted weighted average shares outstanding 29,840 29,392

Debt (Tables)

Debt (Tables)	3 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Schedule of long-term debt	September 30, June 30, Convertible Senior Notes, net $ 117,261 $ 115,829 Mortgage 2,911 2,960 120,172 118,789 Less current portion 197 197 $ 119,975 $ 118,592
Schedule of carrying value of convertible senior notes	September 30, June 30, Principal amount $ 143,750 $ 143,750 Unamortized debt discount (23,044 ) (24,267 ) Unamortized debt issuance costs (3,445 ) (3,654 ) Net carrying value $ 117,261 $ 115,829
Schedule of components of total interest expense related to notes	Three months Contractual coupon $ 725 Amortization of debt discount 1,223 Amortization of debt issuance costs 209 $ 2,157

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Schedule of summary of valuation of financial assets and liabilities	Fair Value Measurements at September 30, 2016 Using Quoted Prices Significant Significant Total Cash equivalents: Time deposits - $ 6,292 - $ 6,292 Investments: Time deposits - 1,910 - 1,910 Foreign currency contracts-liabilities (1) - 38 - 38 Contingent consideration (2) - - $ 135 135 (1) Included in “Accrued expenses” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2016. (2) Included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2016. Fair Value Measurements at June 30, 2016 Using Quoted Prices Significant Significant Total Cash equivalents: Time deposits - $ 6,249 - $ 6,249 Investments: Time deposits - 881 - 881 Foreign currency contracts-assets (3) - 160 - 160 Foreign currency contracts-liabilities (4) - 169 - 169 Contingent consideration (5) - - $ 132 132 (3) Included in “Other receivables” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2016. (4) Included in “Accrued expenses” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2016. (5) Included in “Long-term liabilities” in the accompanying Consolidated Balance Sheet as of June 30, 2016.

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Schedule of segment performance measures	Human Pharmaceutical Performance Unallocated Consolidated 2016 Net sales $ 47,889 $ 40,616 $ 39,513 $ - $ 128,018 Gross profit 14,205 6,954 9,680 - 30,839 Income (loss) before income taxes 3,972 3,067 4,832 (5,091 ) 6,780 2015 Net sales $ 57,481 $ 38,360 $ 37,659 $ - $ 133,500 Gross profit 20,309 6,114 8,158 - 34,581 Income (loss) before income taxes 10,503 2,099 3,544 (1,163 ) 14,983

Stock Based Compensation (Narra

Stock Based Compensation (Narrative) (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016	Dec. 15, 2015	Dec. 06, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,664	$ 1,467
2015 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares of common stock that may be issued				4,250
2010 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares of common stock that may be issued					5,250
Restricted stock | Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock granted, shares	256		221
Restricted stock, vesting period	3 years		3 years
Restricted stock | Non-employee directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock granted, shares			14
Restricted stock, vesting period			1 year
Restricted stock units | Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock granted, shares	42		46
Performance-vested restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock granted, shares	160		142
Restricted stock, vesting period	3 years		3 years
Upper limit of target grant, shares	280		248
Performance-vested restricted stock units, vesting percentage at the end of third year	100.00%		100.00%
Restricted common stock, restricted stock units and stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,659	$ 1,462
Total unrecognized compensation cost	$ 15,142
Performance Stock Options | Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of performance stock options granted	28
Exercise price of performance options granted	$ 20.03
Target price performance stock options	$ 40
Number of trading days	20 days
Explicit service period	1 year
Expiration Date of performance stock options	Jun. 30, 2021
Expiration period of option if target price achieved	10 years

Capital Stock (Narrative) (Deta

Capital Stock (Narrative) (Detail) - $ / shares shares in Thousands	1 Months Ended
	Sep. 20, 2016	Aug. 25, 2016	Sep. 30, 2016	Jun. 30, 2016	May 08, 2014
Dividends Payable [Line Items]
Common stock, shares authorized			75,000	75,000
Preferred stock, shares authorized			2,000	2,000
Dividends declared, per share amount		$ 0.065
Dividend paid, per share amount	$ 0.065
Dividends declared, date of declaration		Aug. 25, 2016
Dividend paid, date		Sep. 20, 2016
Dividends declared, date of record		Sep. 9, 2016
Stock repurchase program
Dividends Payable [Line Items]
Number of shares authorized to be repurchased					5,000

Net Income Per Common Share (Re

Net Income Per Common Share (Reconciliation of Weighted Average Shares Outstanding and Diluted Weighted Average Shares Outstanding) (Detail) - shares shares in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Earnings Per Share [Abstract]
Weighted average shares outstanding	29,518	28,983
Dilutive effect of stock options and restricted stock awards and units	322	409
Diluted weighted average shares outstanding	29,840	29,392

Net Income Per Common Share (Na

Net Income Per Common Share (Narrative) (Detail)	Sep. 30, 2016$ / shares
Earnings Per Share [Abstract]
Senior notes, initial conversion price per share	$ 33.215

Debt (Summary of Long-term Debt

Debt (Summary of Long-term Debt) (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016
Debt Instrument [Line Items]
Mortgage	$ 2,911	$ 2,960
Long-term debt including current portion	120,172	118,789
Less current portion	197	197
Long-term debt, net	119,975	118,592
Convertible Senior Notes, net
Debt Instrument [Line Items]
Long-term debt including current portion	$ 117,261	$ 115,829

Debt (Summary carrying value of

Debt (Summary carrying value of Notes) (Detail 1) - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016
Debt Instrument [Line Items]
Net carrying value	$ 120,172	$ 118,789
Convertible Senior Notes, net
Debt Instrument [Line Items]
Principal amount	143,750	143,750
Unamortized debt discount	(23,044)	(24,267)
Unamortized debt issuance costs	(3,445)	(3,654)
Net carrying value	$ 117,261	$ 115,829

Debt (Summary interest expense

Debt (Summary interest expense related to notes recognized) (Detail 2) - Interest expense $ in Thousands	3 Months Ended
	Sep. 30, 2016USD ($)
Debt Instrument [Line Items]
Contractual coupon	$ 725
Amortization of debt discount	1,223
Amortization of debt issuance costs	209
Interest expense	$ 2,157

Debt (Narrative) (Detail)

Debt (Narrative) (Detail) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended
	Nov. 30, 2015USD ($)Share$ / shares	Sep. 30, 2016USD ($)days$ / shares
Debt Instrument [Line Items]
Aggregate principal amount	$ 143,750
Senior notes, initial conversion price per share | $ / shares		$ 33.215
Convertible Senior Notes, net
Debt Instrument [Line Items]
Aggregate principal amount	125,000
Aggregate principal amount of additional convertible debt	18,750
Aggregate proceeds from convertible senior notes	$ 143,750
Debt interest rate	2.00%
Number of common stock issue in conversion debt | Share	4,328
Senior notes, initial conversion price per share | $ / shares	$ 33.215
Threshold multiple for debt conversion of notes		$ 1,000
Threshold trading days for convertible debt | days		20
Threshold consecutive trading days for convertible debt		30 days
Percentage of minimum stock price trigger for conversion		130.00%
Maximum calculated percentage to which trading price of notes is compared in order to trigger conversion feature of notes		98.00%

Debt (Narrative) (Detail 1)

Debt (Narrative) (Detail 1) - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016	Oct. 28, 2015	Jun. 25, 2015
Debt Instrument [Line Items]
Secured Debt	$ 2,911	$ 2,960
Revolving Bank Loans | Amended and Restated Credit Agreement
Debt Instrument [Line Items]
Aggregate revolving commitment			$ 150,000	$ 75,000
Aggregate amount increase			$ 100,000
ABR Loans | Amended and Restated Credit Agreement | LIBOR | Minimum
Debt Instrument [Line Items]
Adjusted LIBOR Loans at interest rates	0.00%
ABR Loans | Amended and Restated Credit Agreement | LIBOR | Maximum
Debt Instrument [Line Items]
Adjusted LIBOR Loans at interest rates	0.75%
Eurodollar Loans | Amended and Restated Credit Agreement | LIBOR | Minimum
Debt Instrument [Line Items]
Adjusted LIBOR Loans at interest rates	1.00%
Eurodollar Loans | Amended and Restated Credit Agreement | LIBOR | Maximum
Debt Instrument [Line Items]
Adjusted LIBOR Loans at interest rates	1.75%

Debt (Narrative) (Detail 2)

Debt (Narrative) (Detail 2) - USD ($) $ in Thousands	1 Months Ended
	Jun. 30, 2011	Sep. 30, 2016	Jun. 30, 2016
Debt Instrument [Line Items]
Mortgage payable		$ 2,911	$ 2,960
Mortgage payable
Debt Instrument [Line Items]
Mortgage payable	$ 3,947
Mortgage payable, amortization period	20 years
Debt interest rate		4.92%

Commitments, Contingencies an33

Commitments, Contingencies and Other Matters (Narrative) (Detail) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2016USD ($)Entity	Jun. 30, 2009USD ($)	Jun. 30, 2016USD ($)
Commitments and Contingencies Disclosure [Line Items]
Environmental remediation charge	$ 170
Pulvair Site Group
Commitments and Contingencies Disclosure [Line Items]
Loss contingency, damages sought	1,700
Arsynco, Inc
Commitments and Contingencies Disclosure [Line Items]
Accrual for environmental loss contingencies	10,035		$ 12,532
Arsynco, Inc | Minimum
Commitments and Contingencies Disclosure [Line Items]
Site contingency loss exposure not accrued	19,700
Arsynco, Inc | Maximum
Commitments and Contingencies Disclosure [Line Items]
Site contingency loss exposure not accrued	21,500
Arsynco, Inc | Selling, General and Administrative Expenses
Commitments and Contingencies Disclosure [Line Items]
Environmental remediation charge	170
BASF Corporation
Commitments and Contingencies Disclosure [Line Items]
Partial reimbursement of environmental remediation costs previously expensed		$ 550
Gain related to partial reimbursement		550
Environmental remediation costs expensed in prior years		$ 1,200
Future remediation costs receivable	4,515		$ 5,639
Subsidiary
Commitments and Contingencies Disclosure [Line Items]
Amount expected to be paid for product registrations and various task force groups	$ 1,826
Berry's Creek Study Area | Arsynco, Inc
Commitments and Contingencies Disclosure [Line Items]
Number of potentially responsible parties | Entity	150

Fair Value Measurements (Summar

Fair Value Measurements (Summary of Valuation of Financial Assets and Liabilities) (Detail) - USD ($) $ in Thousands		Sep. 30, 2016		Jun. 30, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts-assets	[1]			$ 160
Foreign currency contracts-liabilities		$ 38	[2]	169	[3]
Contingent consideration		135	[4]	132	[5]
Time deposits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		6,292		6,249
Investments		1,910		881
Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts-assets	[1]
Foreign currency contracts-liabilities			[2]		[3]
Contingent consideration			[4]		[5]
Quoted Prices in Active Markets (Level 1) | Time deposits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Investments
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts-assets	[1]			160
Foreign currency contracts-liabilities		38	[2]	169	[3]
Contingent consideration			[4]		[5]
Significant Other Observable Inputs (Level 2) | Time deposits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		6,292		6,249
Investments		1,910		881
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts-assets	[1]
Foreign currency contracts-liabilities			[2]		[3]
Contingent consideration		135	[4]	132	[5]
Significant Unobservable Inputs (Level 3) | Time deposits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Investments
[1]	Included in "Other receivables" in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2016.
[2]	Included in "Accrued expenses" in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2016.
[3]	Included in "Accrued expenses" in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2016.
[4]	Included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2016.
[5]	Included in "Long-term liabilities" in the accompanying Consolidated Balance Sheet as of June 30, 2016.

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Detail) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Nov. 30, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate principal amount			$ 143,750
Theoretical borrowing rate used to calculate fair value of debt			6.50%
Fair value of the notes	$ 131,800
Foreign currency contract
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, notional amount	55,921
Unrealized losses on hedging activities	$ (36)	$ (251)

Segment Information (Summary of

Segment Information (Summary of Segment Perfomance Measures by Segment) (Detail) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Segment Reporting Information [Line Items]
Net sales	$ 128,018	$ 133,500
Gross profit	30,839	34,581
Income (loss) before income taxes	6,780	14,983
Operating Segments | Human Health
Segment Reporting Information [Line Items]
Net sales	47,889	57,481
Gross profit	14,205	20,309
Income (loss) before income taxes	3,972	10,503
Operating Segments | Pharmaceutical Ingredients
Segment Reporting Information [Line Items]
Net sales	40,616	38,360
Gross profit	6,954	6,114
Income (loss) before income taxes	3,067	2,099
Operating Segments | Performance Chemicals
Segment Reporting Information [Line Items]
Net sales	39,513	37,659
Gross profit	9,680	8,158
Income (loss) before income taxes	4,832	3,544
Unallocated Corporate
Segment Reporting Information [Line Items]
Net sales
Gross profit
Income (loss) before income taxes	$ (5,091)	$ (1,163)

Segment Information (Narrative)

Segment Information (Narrative) (Detail)	3 Months Ended
	Sep. 30, 2016Segment
Segment Reporting [Abstract]
Number of operating segments	3

Subsequent Event (Narrative) (D

Subsequent Event (Narrative) (Detail) - Subsequent Event - Purchase Agreement $ in Thousands	1 Months Ended
	Nov. 02, 2016USD ($)Subsidiaryshares
Subsequent Event [Line Items]
Number of wholly-owned subsidiaries | Subsidiary	2
Payment of purchase price	$ 320,000
Number of share issued | shares	5,122
Purchase price, earn-out amount	$ 50,000
Payable on closing date of acquisition
Subsequent Event [Line Items]
Payment of purchase price	270,000
Payable on fifth anniversary of closing date
Subsequent Event [Line Items]
Payment of purchase price	$ 50,000
Issued to Sellers on the third anniversary of closing
Subsequent Event [Line Items]
Share issued, percentage	75.00%
Issued on fourth anniversary of closing
Subsequent Event [Line Items]
Share issued, percentage	25.00%